Navigation Links
Selexis SA to Present at Biotech Showcase 2012

GENEVA, Switzerland, Jan. 5, 2012  /PRNewswire/ -- Selexis SA announced today the Company's president and CEO, Igor Fisch, Ph.D., will present at the Biotech Showcase 2012 Conference held in conjunction with the annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Dr. Fisch will present, "Translating Drug Discovery into Clinical Success: A Growth Investment" to prospective investors and corporate partners on Monday, January 9 at 11:00 AM in the Stockton Room at the Park 55 Wyndham.   The presentation will cover existing commercial offerings, the expansion of the SUREtechnology Platform™ and new market opportunities in drug discovery, next generation biologics and difficult to express proteins. 

"Biotech Showcase is an ideal opportunity for us to highlight our innovations and our applications of the SUREtechnology Platform™ supporting the biopharmaceutical industry's drug discovery efforts," said Dr. Fisch.  "Using Selexis' platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.  The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.  The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information, visit

Selexis SA
Robert Meister
(602) 953-1716

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. InterMune to Present at Canaccord Adams Conference
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):